MetLife Investment Management’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $327K | Buy |
27,254
+7,224
| +36% | +$60K | ﹤0.01% | 2148 |
|
|
2026
Q1 | $168K | Sell |
20,030
-6,210
| -24% | -$65.2K | ﹤0.01% | 2312 |
|
|
2025
Q4 | $378K | Hold |
26,240
| – | – | ﹤0.01% | 1927 |
|
|
2025
Q3 | $253K | Hold |
26,240
| – | – | ﹤0.01% | 2185 |
|
|
2025
Q2 | $215K | Buy |
26,240
+2,694
| +11% | +$22.6K | ﹤0.01% | 2150 |
|
|
2025
Q1 | $168K | Sell |
23,546
-3,643
| -13% | -$27.1K | ﹤0.01% | 2287 |
|
|
2024
Q4 | $210K | Hold |
27,189
| – | – | ﹤0.01% | 2282 |
|
|
2024
Q3 | $285K | Hold |
27,189
| – | – | ﹤0.01% | 2094 |
|
|
2024
Q2 | $318K | Buy |
27,189
+6,740
| +33% | +$105K | ﹤0.01% | 1969 |
|
|
2024
Q1 | $431K | Sell |
20,449
-1,878
| -8% | -$33.4K | ﹤0.01% | 1758 |
|
|
2023
Q4 | $401K | Hold |
22,327
| – | – | ﹤0.01% | 1821 |
|
|
2023
Q3 | $368K | Hold |
22,327
| – | – | ﹤0.01% | 1815 |
|
|
2023
Q2 | $446K | Hold |
22,327
| – | – | ﹤0.01% | 1770 |
|
|
2023
Q1 | $422K | Hold |
22,327
| – | – | ﹤0.01% | 1748 |
|
|
2022
Q4 | $506K | Sell |
22,327
-935
| -4% | -$21.1K | ﹤0.01% | 1638 |
|
|
2022
Q3 | $615K | Buy |
23,262
+2,096
| +10% | +$62.2K | 0.01% | 1483 |
|
|
2022
Q2 | $523K | Sell |
21,166
-2,326
| -10% | -$58.1K | ﹤0.01% | 1628 |
|
|
2022
Q1 | $780K | Buy |
23,492
+8,295
| +55% | +$230K | 0.01% | 1486 |
|
|
2021
Q4 | $497K | Hold |
15,197
| – | – | ﹤0.01% | 1508 |
|
|
2021
Q3 | $637K | Hold |
15,197
| – | – | 0.01% | 1390 |
|
|
2021
Q2 | $590K | Hold |
15,197
| – | – | 0.01% | 1474 |
|
|
2021
Q1 | $518K | Hold |
15,197
| – | – | ﹤0.01% | 1503 |
|
|
2020
Q4 | $689K | Hold |
15,197
| – | – | 0.01% | 1313 |
|
|
2020
Q3 | $418K | Hold |
15,197
| – | – | ﹤0.01% | 1457 |
|
|
2020
Q2 | $560K | Hold |
15,197
| – | – | 0.01% | 1318 |
|
|
2020
Q1 | $492K | Hold |
15,197
| – | – | 0.01% | 1224 |
|
|
2019
Q4 | $623K | Hold |
15,197
| – | – | 0.01% | 1332 |
|
|
2019
Q3 | $541K | Hold |
15,197
| – | – | 0.01% | 1377 |
|
|
2019
Q2 | $781K | Sell |
15,197
-27,082
| -64% | -$1.35M | 0.01% | 1234 |
|
|
2019
Q1 | $2.42M | Buy |
42,279
+28,186
| +200% | +$1.4M | 0.01% | 1158 |
|
|
2018
Q4 | $591K | Hold |
14,093
| – | – | 0.01% | 1263 |
|
|
2018
Q3 | $1.06M | Buy |
14,093
+876
| +7% | +$63.1K | 0.01% | 1098 |
|
|
2018
Q2 | $948K | Hold |
13,217
| – | – | 0.01% | 1043 |
|
|
2018
Q1 | $395K | Hold |
13,217
| – | – | ﹤0.01% | 1514 |
|
|
2017
Q4 | $439K | Buy |
+13,217
| New | +$398K | 0.01% | 1471 |
|
Other funds holding RGNX
RG
MetLife Investment Management's RGNX Position: Q2 2026 in Review
MetLife Investment Management increased its Regenxbio (RGNX) stake by 36% in Q2 2026, buying an estimated $60K and bringing the position to 27,254 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #2148.
MetLife Investment Management first reported a position in RGNX in Q4 2017 and has held it in 35 quarters since. The position peaked at $2.42M in Q1 2019. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- MetLife Investment Management held 27,254 shares of Regenxbio worth $327K as of Q2 2026.
- MetLife Investment Management bought 7,224 Regenxbio shares in Q2 2026, an estimated $60K.
- Regenxbio made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2148 holding.
- MetLife Investment Management first reported a position in Regenxbio in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Regenxbio position peaked at $2.42M in Q1 2019.
- 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.